Clinical Trial Update: Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AS101 for chemotherapy-induced thrombocytopenia in solid tumor patients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Thrombocytopenia

Drugs mentioned

• AS101

Snippet

Sponsor: BioMAS Ltd | Conditions: Chemotherapy Induced Thrombocytopenia | Phase 2 | Status: TERMINATED